Colorectal cancer(CRC)is known to harbor considerable heterogeneity.1 Consequently,it could be hypothesized that similar-appearing tumors might exhibit substantial genetic differences while diverse-appearing tumors ma...Colorectal cancer(CRC)is known to harbor considerable heterogeneity.1 Consequently,it could be hypothesized that similar-appearing tumors might exhibit substantial genetic differences while diverse-appearing tumors may have a similar genetic landscape.2 Due to these differences at the molecular level,they behave or respond differently to therapies as well.CRC progression is a multistep process and involves the accumulation of substantial genetic and epigenetic events in a stage-dependent manner.展开更多
Molecular subtypes-based therapies offer new potential framework for desired and precise outcome in clinical settings.Current treatment strategies in colorectal cancer are largely‘one drug fit all’model for patients...Molecular subtypes-based therapies offer new potential framework for desired and precise outcome in clinical settings.Current treatment strategies in colorectal cancer are largely‘one drug fit all’model for patients that display same pathological conditions.However,CRC is a very heterogenous set ofmalignancy that does not support for above criteria.Each subtype displays different pathological and genetic signatures.Based on these features,therapeutic stratification for individual patients may be designed,which may ultimately lead to improved therapeutic outcomes.In this comprehensive review,we have attempted to briefly outline major CRC pathways.A detailed overview of molecular subtypes and their clinical significance has been discussed.Present and futuremethods,governing CRC subtyping in the era of personalized therapywith a special emphasis on CMS subtypes of CRC has been reviewed.Together,discovery and validation of new CRC patient stratification methods,screening for novel therapeutic targets,and enhanced diagnosis of CRC may improve the treatment outcome.展开更多
基金funded by the Department of Biotechnology India section order 6242-P103/RGCB/PMD/DBT/SMSV/2015.
文摘Colorectal cancer(CRC)is known to harbor considerable heterogeneity.1 Consequently,it could be hypothesized that similar-appearing tumors might exhibit substantial genetic differences while diverse-appearing tumors may have a similar genetic landscape.2 Due to these differences at the molecular level,they behave or respond differently to therapies as well.CRC progression is a multistep process and involves the accumulation of substantial genetic and epigenetic events in a stage-dependent manner.
基金The study is supported by Department of Biotechnology grant no.6242-P103/RGCB/PMD/DBT/SMSV/2015.Authors are thankful to the Ministry of Human Resource and Development,and CSIR Govt.of India,New Delhi,India for providing scholarship during this tenure.The authors acknowledge Dr.Tonima Kamat for critically reviewing the manuscript.
文摘Molecular subtypes-based therapies offer new potential framework for desired and precise outcome in clinical settings.Current treatment strategies in colorectal cancer are largely‘one drug fit all’model for patients that display same pathological conditions.However,CRC is a very heterogenous set ofmalignancy that does not support for above criteria.Each subtype displays different pathological and genetic signatures.Based on these features,therapeutic stratification for individual patients may be designed,which may ultimately lead to improved therapeutic outcomes.In this comprehensive review,we have attempted to briefly outline major CRC pathways.A detailed overview of molecular subtypes and their clinical significance has been discussed.Present and futuremethods,governing CRC subtyping in the era of personalized therapywith a special emphasis on CMS subtypes of CRC has been reviewed.Together,discovery and validation of new CRC patient stratification methods,screening for novel therapeutic targets,and enhanced diagnosis of CRC may improve the treatment outcome.
